Format

Send to

Choose Destination
Nat Rev Drug Discov. 2014 Sep;13(9):673-91. doi: 10.1038/nrd4360. Epub 2014 Aug 18.

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Author information

1
Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia.
2
1] Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia. [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville 3052, Victoria, Australia.

Abstract

Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.

PMID:
25131830
DOI:
10.1038/nrd4360
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center